Impact of SARS-CoV-2 Pandemic on Vascular Liver Diseases
| Autor: | Anna Baiges, Eira Cerda, Caroline Amicone, Luis Téllez, Edilmar Alvarado-Tapias, Angela Puente, Jose Ignacio Fortea, Elba Llop, Filipa Rocha, Lara Orts, Oliva Ros-Fargas, Pamela Vizcarra, Kamal Zekrini, Ould Amara Lounes, Ghiles Touati, Natalia Jiménez-Esquivel, Maria Jose Serrano, Angels Falgà, Marta Magaz, Pol Olivas, Fabian Betancourt, Valeria Perez-Campuzano, Fanny Turon, Audrey Payancé, Odile Goria, Pierre-Emmanuel Rautou, Virginia Hernández-Gea, Candid Villanueva, Agustin Albillos, Aurélie Plessier, Juan-Carlos García-Pagán |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Hepatology
SARS-CoV-2 portosinusoidal vascular disease Liver Diseases Malalties del fetge Budd Chiari Syndrome Gastroenterology COVID-19 Portosinusoidal Vascular Disease vascular liver diseases Splanchnic Vein Thrombosis Malalties vasculars Article splanchnic vein thrombosis Humans Vascular Liver Diseases Vascular Diseases Budd Chiari syndrome Pandemics Vascular diseases Liver diseases |
| Zdroj: | Clinical Gastroenterology and Hepatology r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname Dipòsit Digital de la UB Universidad de Barcelona |
| ISSN: | 1542-3565 |
| DOI: | 10.1016/j.cgh.2021.12.032 |
| Popis: | Background & Aims: Vascular liver diseases (VLDs) are represented mainly by portosinusoidal vascular disease (PSVD), noncirrhotic splanchnic vein thrombosis (SVT), and Budd Chiari syndrome (BCS). It is unknown whether patients with VLDs constitute a high-risk population for complications and greater coronavirus disease 2019 (COVID-19)-related mortality from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Our objective was to assess the prevalence and severity of SARS-CoV-2 infection among patients with VLDs, as well as to assess its impact on hepatic decompensation and survival. Methods: This is an observational international study analyzing the prevalence and severity of SARS-CoV-2 infection in VLDs between March 2020 and March 2021, compared with the general population (GP). Patients from Spain (5 centers; n = 493) and France (1 center; n = 475) were included. Results: Nine hundred sixty-eight patients were included: 274 with PSVD, 539 with SVT, and 155 with BCS. Among them, 138 (14%) were infected with SARS-CoV-2: 53 with PSVD, 77 with SVT, and 8 with BCS. The prevalence of SARS-CoV-2 infection in patients with PSVD (19%) and SVT (14%) was significantly higher than in the GP (6.5%; P < .05), whereas it was very similar in patients with BCS (5%). In terms of infection severity, patients with VLDs also presented a higher need of hospital admission (14% vs 7.3%; P < .01), intensive care unit admission (2% vs 0.7%; P < .01), and mortality (4% vs 1.5%; P < .05) than the GP. Previous history of ascites (50% vs 8%; P < .05) and post-COVID-19 hepatic decompensation (50% vs 4%; P < .05) were associated with COVID-19 mortality. Conclusions: Patients with PSVD and SVT could be at higher risk of infection by SARS-CoV-2 and at higher risk of severe COVID-19 disease. © 2021 AGA Institute |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|